Skip to main content
TipRanks
Go Ultimate75% OFF

IRLAB Therapeutics AB Class A (6IRA) Income Statement

1 Followers

IRLAB Therapeutics AB Class A Income Statement

Last quarter (Q3 2026), IRLAB Therapeutics AB Class A's total revenue was kr6.93M, a decrease of 63.22% from the same quarter last year. In Q3, IRLAB Therapeutics AB Class A's net income was kr-13.15M. See IRLAB Therapeutics AB Class A’s key income statements, including revenue, expenses, profit, and income.

Income Statement
Income StatementDec 25Dec 24Dec 23Dec 22Dec 21
kr 57.46Mkr 94.63Mkr 5.68Mkr 61.14Mkr 207.78M
kr -92.35Mkr -92.42Mkr -122.73Mkr -111.23Mkr 168.69M
kr 144.48Mkr 33.45Mkr 58.03Mkr 174.25Mkr 116.11M
Depreciation and Amortizationkr 4.32Mkr 4.58Mkr 4.32Mkr 3.98Mkr 3.47M
kr -88.03Mkr -68.07Mkr -173.32Mkr -109.13Mkr 56.05M
kr -92.35Mkr -75.11Mkr -180.76Mkr -113.11Mkr 52.58M
kr -17.66Mkr -8.02Mkr 2.93Mkr -296.00Kkr -795.00K
kr -110.01Mkr -83.13Mkr -177.84Mkr -113.41Mkr 51.78M
kr -110.01Mkr -83.13Mkr -177.84Mkr -114.20Mkr 51.78M
Per Share Metrics
Basic EPSkr -1.64kr -1.60kr -3.43kr -2.20kr 1.00
Diluted EPSkr -1.64kr -1.60kr -3.43kr -2.20kr 1.00
Weighted Average Shares Outstanding67.00M51.87M51.87M51.83M51.75M
Weighted Average Shares Outstanding (Diluted)67.00M51.87M51.87M51.83M51.75M

Currency in SEK

IRLAB Therapeutics AB Class A Earnings and Revenue History

-200M0200M400M-500000 %-250000 %0 %250000 %EarningsProfit Margin201720182019202020212022202320242025RevenueEarningsProfit Margin